share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Smither John W

Arcutis Biotherapeutics | 4：持股變動聲明-高管 Smither John W

SEC announcement ·  02/15 18:28
Moomoo AI 已提取核心訊息
Arcutis Biotherapeutics, Inc. (ARQT) reported that its Chief Financial Officer, John W Smither, acquired a total of 11,365 shares of common stock on February 13, 2024. The transactions were classified as 'A' for acquisition under the transaction code, indicating they were likely grants or awards. Following these acquisitions, Smither directly holds 11,365 shares. Additionally, it was disclosed that Smither indirectly holds 141,392 shares of Arcutis Biotherapeutics common stock through a trust.
Arcutis Biotherapeutics, Inc. (ARQT) reported that its Chief Financial Officer, John W Smither, acquired a total of 11,365 shares of common stock on February 13, 2024. The transactions were classified as 'A' for acquisition under the transaction code, indicating they were likely grants or awards. Following these acquisitions, Smither directly holds 11,365 shares. Additionally, it was disclosed that Smither indirectly holds 141,392 shares of Arcutis Biotherapeutics common stock through a trust.
Arcutis Biotherapeutics, Inc.（ARQT）報告稱，其首席財務官約翰·史密瑟於2024年2月13日共收購了11,365股普通股。根據交易代碼，這些交易被歸類爲收購交易的 “A”，這表明它們很可能是補助金或獎勵。在這些收購之後，史密瑟直接持有11,365股股票。此外，據透露，史密瑟通過信託間接持有141,392股Arcutis Biotherapeutics普通股。
Arcutis Biotherapeutics, Inc.（ARQT）報告稱，其首席財務官約翰·史密瑟於2024年2月13日共收購了11,365股普通股。根據交易代碼，這些交易被歸類爲收購交易的 “A”，這表明它們很可能是補助金或獎勵。在這些收購之後，史密瑟直接持有11,365股股票。此外，據透露，史密瑟通過信託間接持有141,392股Arcutis Biotherapeutics普通股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息